tokens: Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3',5'-monophosphate ). Thereby , a clinical study of the combined administration of the two agents was attempted .